IS CHINA’S BIOTECH BOOM AT RISK? FEAR OF POLICY BACKLASH AFTER DEATH IN GENE-EDITING TRIAL

The death of a six-year-old girl after receiving an experimental gene-editing therapy has been described by scientists as a tragedy that highlights the need to improve trial safeguards. But some in the biotechnology industry fear Chinese policymakers may curtail the regulatory flexibility that scientists have long enjoyed in initiating clinical trials – a key mechanism behind China’s competitive edge…

News - South China Morning Post reports that the death of a six-year-old girl after receiving an experimental gene-editing therapy has been described by scientists as a tragedy that highlights the need to improve trial safeguards.

The report adds: But some in the biotechnology industry fear Chinese policymakers may curtail the regulatory flexibility that scientists have long enjoyed in initiating clinical trials – a key mechanism behind China’s competitive edge…

“I hope this tragedy does not have a lasting negative impact on China’s...

This report is covered across the current DAMMNEWS feeds. Policy stories matter because a statement is not always a final decision. The next useful detail is normally what has formally changed, who is affected and when it takes effect.

This is a developing report. DAMMNEWS will surface related coverage as closely matched reporting enters the live cache.

DAMMNEWS RSS BRIEFING — generated locally from the available News - South China Morning Post headline and RSS excerpt. It is not a summary of the full source article.